MacroGenics | MGNX - Cost Of Sales


MacroGenics reported $10.12M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Genmab DKK 81M 23M Dec/2025
Geron USD 1.69M 386K Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 2.94B 380M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Xencor USD 61.66M 50.95M Jun/2025